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ABSTRACT
Sequence diversity and immunodominance are major obstacles in the design of an effective vaccine
against HIV. HIV Env is a highly-glycosylated protein composed of ‘conserved’ and ‘variable’ regions. The
latter contains immunodominant epitopes that are frequently targeted by the immune system resulting in
the generation of immune escape variants. This work describes 12 regions in HIV Env that are highly
conserved throughout the known HIV M Group sequences (Env CE), and are poorly immunogenic in
macaques vaccinated with full-length Env expressing DNA vaccines. Two versions of plasmids encoding
the 12 Env CE were generated, differing by 0–5 AA per CE to maximize the inclusion of commonly
detected variants. In contrast to the full-length env DNA vaccine, vaccination of macaques with a
combination of these 2 Env CE DNA induced robust, durable cellular immune responses with a signiﬁcant
fraction of CD8C T cells with cytotoxic phenotype (Granzyme BC and CD107aC). Although inefﬁcient in
generating primary responses to the CE, boosting of the Env CE DNA primed macaques with the intact env
DNA vaccine potently augmented pre-existing immunity, increasing magnitude, breadth and cytotoxicity
of the cellular responses. Fine mapping showed that 7 of the 12 CE elicited T cell responses. Env CE DNA
also induced humoral responses able to recognize the full-length Env. Env CE plasmids are therefore
capable of inducing durable responses to highly conserved regions of Env that are frequently absent after
Env vaccination or immunologically subdominant. These modiﬁed antigens are candidates for use as
prophylactic and therapeutic HIV vaccines.
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Introduction
The variability of HIV is a major stumbling block for the design
of a universal vaccine. The plasticity of HIV allows for an enor-
mous number of viable mutant strains, which in turn allows
the virus to escape from immune responses while preserving
viral function. Presentation of variable epitopes results in
immune response easily overcome by virus mutation and
escape. Immunodominance (i.e., hierarchical preference for
recognition of one epitope of the vaccine over another) and
generation of immune responses targeting non-protective epit-
opes can interfere or even suppress responses toward con-
served, and ideally protective, segments in the viral proteome.
Non-protective epitopes are those whose recognition is associ-
ated with a lack of virologic containment in vivo (e.g., high viral
load) or those that can readily escape without impairing viral
ﬁtness. Immunodominant epitopes with a high degree of con-
servation do not necessarily confer immune control of viral
replication, as they may represent viral adaptation to human
HLA types at the population level, and at minimal ﬁtness
cost.1-3 It seems likely that if HIV segments were capable of
mutating without limiting virus functionality, they would not
contribute substantially to a vaccine’s protective response. Vari-
able epitopes could serve as immunodominant “decoys” that
can absorb immune reactivity and potentially preclude
responses against protective epitopes. The mechanism respon-
sible for the immunodominance of the variable regions is
poorly understood but, clearly, provides an advantage for the
persistence of the virus. For example, the most signiﬁcant dif-
ference between HIV strains infecting vaccine vs. placebo recip-
ients in the Step (HVTN 502) vaccine trial occurred within a
region including the SLYNTVATL epitope in Gag,4 an immu-
nodominant epitope, and immune responses to which are not
associated with diminution of viral load.5 The SLYNTVATL
reactivity may therefore represent an immunodominant decoy
response that is detrimental to vaccine efﬁcacy.6
HIV vaccine immunogens have generally been derived from
individual viral isolates. It may not be possible in a vaccine to cover
all the viral antigenic diversity required to block viable or
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transition escape forms of the virus—as rapid, sequential epitope
evolution, including uncommon intermediates, is commonplace
early in infection.7,8 The immunogen sequence diversity that may
be required to block viable or transition escape mutants may be
too large to accommodate for a single or a manageably sized varia-
tion inclusive vaccine. To maximize immunologic breadth, differ-
ent strategies are being explored to block common escape forms of
viruses and thus effectively block immunological escape pathways
that (i) use consensus and deduced ancestral sequences,9-11 and
(ii) create antigenic combinations of common variants that evolve
as a result of immune pressure (e.g., mosaics12-14,15 and similar
structures.16,17 We18-21 and others22-25 have designed vaccine
approaches aiming to focus the immune responses to conserved
regions of the virus.
We previously reported the generation of novel immunogens
that focus the immune responses to conserved regions in HIV
gag.19,20 These Conserved Elements (CE) were deﬁned based on
stringent conservation, functional importance and independence
of ‘protective’ haplotypes associated with HIV control.26-29 In this
report, we expanded this vaccine strategy to include conserved
regions of Env. We continue to use DNA as vaccine platform since
it has several advantages such as simplicity, scalability and possibil-
ity for repeated applications due to the lack of immunity against
the vector. The combination of DNA intramuscular delivery fol-
lowing by in vivo electroporation has induced promising immune
responses in macaques and in humans (reviewed in30, 31).
Results
Identiﬁcation of Env CE
Sequence data set and amino acid database frequencies. Full-
length HIV-1 group M Env coding sequences were downloaded
from the HIV database (HIVDB, http://www.hiv.lanl.gov/). Any
sequences with hypermutations32 early stop codons, frame-shift
mutations or ambiguous amino acids were excluded. A multi-
ple sequence alignment was prepared using MUSCLE33 and
then manually edited. The database frequency of each amino
acid at each site in the ﬁnal alignment was then calculated using
a perl script (http://indra.mullins.microbiol.washington.edu/
perlscript/docs/CountAAFreq.html). The degree of conserva-
tion required for inclusion as an Env CE was at least 90% across
the entire HIV-1 M group, and usually at least 98%. Regions for
inclusion/exclusion from the vaccine were also selected based
on whether immune responses to such regions were associated
with virologic control or lack of control, and whether mutations
at a given site had been shown to result in a loss of viral ﬁtness
ex vivo. Other features that resulted in a relaxation of the 90%
requirement was an association with known function or CTL
escape resulting in a loss in viral ﬁtness, or to substantially
extend the length of a CE. For example, the CD4 binding loop
region of the HIV Env protein corresponds to a region that
binds to broadly neutralizing antibodies and this region is
included as CE10. To include this region, 7 toggle sites were
used and one residue was included in CE10 without a toggle
that had a conservation level of only 79%. In another example,
a very long CE (CE14; 43 AA) was included by allowing 5 tog-
gle sites and one residue was conserved only at a level of 84%
across the HIV-1 M group. However, this site was conserved at
97% and 99% in HIV-1 M group subtypes B and C and no
obvious toggle site was required. A set of 12 conserved elements
(CE) was identiﬁed in the HIV Env protein (Table 1) spanning
11, 14, 21, 15, 23, 21, 13, 12, 14, 43, 20, and 13 AA in length.
The localization of the CE within HXB2 Env as reference is
shown (Table 1). Toggle sites were used to create 2 versions of
all the CE, except CE6 (gray shaded in Table 1). A toggle site
represents an amino acid site at which conservation may be
low but at which 2 amino acids combined account for most of
sequences of all HIV-1 M group sequences known, usually 98–
100%. HIV-1 M group subtypes B, primarily found in the
Americas and Western Europe, and subtype C primarily found
in South Africa and India, represent most of the available
sequence data, and together they represent > 60% of all HIV-1
infections. Toggle sites often represent AA that are highly con-
served in either subtype B or C, and the Env CE1 and CE2
sequences correspond to the AA most associated with subtypes
B and C, respectively, if the consensus or second most common
variant residues differed.
Env CE are poorly immunogenic in env DNA vaccinated
macaques
The immunogenicity of the 12 CE identiﬁed within HIV env
was evaluated in samples from 16 macaques vaccinated with
DNA expressing intact Env as part of other studies (Table 2).
The animals received a mixture of clade B (including BaL) and
C env DNA administered via the IM route followed by in vivo
electroporation. PBMC collected 2 weeks after the 2nd or 3rd
vaccination were stimulated with (i) Env-speciﬁc peptide pools
(15-mer peptides overlapping by 11 AA derived from BaL)
spanning the complete Env and (ii) a CE-speciﬁc peptide pool
consisting of 10-mer peptides overlapping by 9 AA and 15-mer
Table 1. Sequence and localization of the Env CE.
CE# Sequence
Position in
HXB2
Location in
Env
CE6 WVTVYYGVPVW 35–45 C1
CE1–1 HNVWATHACVPTDP 66–79 C1
CE1–2 HNIWATHACVPTDP
CE7–1 ISLWDQSLKPCVKLTPLCVTL 109–123 C1
CE7–2 ISLWDESLKPCVKLTPLCVTL
CE8–1 FEPIPIHYCTPAGFA 210–224 C2
CE8–2 FDPIPIHYCAPAGYA
CE9–1 VQCTHGIRPVVSTQLLLNGSLAE 245–267 C2
CE9–2 VQCTHGIKPVVSTQLLLNGSLAE
CE10–1 SGGDPEIVMHSFNCGGEFFYC 365–385 C3
CE10–2 AGGDLEITTHSFNCRGEFFYC
CE11–1 DNWRSELYKYKVV 478–489 C5
CE11–2 NNWRSELYKYKVV
CE12–1 ARRRVVQREKRA 502–512 C5
CE12–2 AKRRVVEREKRA
CE13–1 GFLGTAGSTMGAAS 521–534 Fusion
PeptideCE13–2 GFLGAAGSTMGAAS
CE14–1 LTVQARLLLSGIVQQQNNLLRAIEA
QQHLLQLTVWGIKQLQAR
537–579 N-heptad
CE14–2 LTVQARQLLSGIVQQQSNLLKAIEA
QQHMLQLTVWGIKQLQTR
CE15–1 WLWYIKIFIMIVGGLVGLRI 678–697 MPER-MSD
CE15–2 WLWYIRIFIMIVGGLIGLRI
CE16–1 RVRKGYSPLSLQT 707–720 MSD
CE16–2 RVRQGYSPLSFQT
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peptides overlapping by 11 AA designed to maximize the detec-
tion of CD4C and CD8C T cell responses (Table 2). Fig. 1 dis-
plays the CE- and Env-speciﬁc T cell responses in these
animals ranked according to the magnitude of Env-speciﬁc
responses, and the presence or lack of CE-speciﬁc responses.
Despite mounting robust Env-speciﬁc T cell reponses, »50% of
the macaques failed to develop Env CE-speciﬁc responses
(Fig. 1). The absence of CE-speciﬁc T cell responses was not
related to the number of vaccinations (2 or 3) or the form of
Env used in the vaccine (gp160, soluble trimeric gp140 or
membrane-associated gp145 (Table 2). Comparison of the
magnitude of the T cell responses to gp120 Env and CE further
showed that, expect one animal (T145), there is a skewing of
the responses toward gp120, indicating that the majority of the
responses target epitopes in the more variable regions. Mapping
of individual Env CE responses in 5 of the animals (using 12
individual peptides pools covering both Env CE variants)
showed that only 1 or 2 CE were recognized (Table 3). These
data indicate that the 12 Env CE are poorly immunogenic
when present within the complete Env protein, perhaps due to
immunological interference with other epitopes. This ﬁnding is
reminiscent of our reported data on the HIV Gag CE and SIV
Gag CE.18, 20
Generation of Env CE DNA vaccine
To promote the induction of Env CE-speciﬁc cellular immune
responses, we designed and synthesized 2 versions of synthetic
proteins (Env CE1 and Env CE2), each of which is composed
of 12 conserved elements (Fig. 2A). Env CE1 and Env CE2
proteins differ by 0–5 amino acid per CE to maximize the
coverage of common HIV variants. The CE were collinearly
arranged and separated by short amino acid linkers (e.g.,3
amino acids) designed to facilitate processing of the protein
and avoidance of neo-antigens.34,35 The coding sequences for
Env CE1 and Env CE2 proteins were RNA/codon-optimized
to maximize expression in mammalian cells and placed into a
eukaryotic DNA plasmid vector, pCMVkan,36 between the
human CMV promoter and bovine growth hormone poly A
signal. The pCMVkan expression vector is optimized for opti-
mal growth in bacteria (kanR) and expression of the insert in
mammalian cells. The Env CE1 and Env CE2 proteins were
expressed upon transient transfection of HEK293 cells
(Fig. 2B). Env CE2 accumulated to higher level than Env CE1,
possibly due to the 24 AA difference in these proteins, which
could affect protein stability. In comparison, transfection of
plasmids expressing gp145 Env proteins of BaL, 6101 and
1086 produced proteins that are found in both the cell-associ-
ated fraction (gp145) and the supernatant (processed gp120).
Using FLAG-tagged version of the expression vectors to visu-
alize the proteins efﬁciently, Env CE1 and Env CE2 proteins
were found in the cytoplasm in a punctuate pattern in the
perinuclear area of transfected HeLa cells (Fig. 2D). Western
immunoblot analysis further showed that Env CE1 and Env
CE2 proteins migrate as 2 bands found exclusively in the cell-
associated fraction (Fig. 2B). To understand the nature of the
2 bands, cell extracts from HEK293 transfected cells were sub-
jected to in vitro digestion with Endoglycosidase H (EndoH)
and N-Glycosidase F (PNGase F), commonly used to interro-
gate protein glycosylation (Fig. 2C). Endo H removes man-
nose-rich oligosaccharides, but cannot cleave complex
oligosaccharide structures, whereas PNGase F removes all N-
linked carbohydrates. Both Env CE1 and Env CE2 proteins
Table 2. env DNA vaccine and T cell responses in vaccinated macaques.
Animal
ID
Env
(strain and
form)
# of
vaccinations
Dose
(total)
Env(%
IFN-gT
cells)
Env CE(%
IFN-gT
cells)
P909 rhFLSC, BaL,
6101, 1086,
and env C
gp160
and
gp140
2 3 mg 0.07 0.03
P914 0.02 0
P917 0.17 0
P919 0.12 0
P923 0.04 0
P929 0.24 0.02
P934 0.17 0.13
P937 0.29 0.09
P941 0.21 0.14
T134 6101, BaL and
1086
gp145 3 2 mg 0.15 0.09
T135 0.06 0.05
T140 0.11 0.13
T142 0.12 0
T145 0.80 0.84
T146 0.03 0
T151 0.08 0
Figure 1. CE are poorly immunogenic in env DNA vaccinated macaques. Analysis
of Env CE T cell responses in 16 macaques immunized with a mixture of DNA
expressing full-length Env including HIV-1 BaL. Env-speciﬁc IFN-g T cell responses
were measured using a matching peptide pool of HIV Env clade B strain BaL span-
ning gp120. CE-speciﬁc IFN-gC T responses were measured using a peptide pool
(mixture of 15-mer overlapping by 11 AA and 10-mer overlapping by 9 AA) cover-
ing the 12 CE.
Table 3. Mapping of CE responses in selected macaques after vaccination with full-
length HIV env DNA.
Animal ID
P909 P929 P934 P937 P941
CE6
CE1
CE7
CE8
CE9 C
CE10 C
CE11
CE12
CE13
CE14 C C C C
CE15
CE16
No. of Positive CE/animal 1 1 1 1 2
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were sensitive to both endoglycosidases indicating that these
proteins underwent posttranslational modiﬁcations. Thus, the
2 bands represent different glycosylation forms of the Env CE
proteins. As positive control, an extract containing the intact
gp145 Env protein (BaL) was used (Fig. 2C, bottom panel).
We noted that the anti-gp120 serum used to visualize Env on
the Western blot recognized the deglycosylated gp145 to a
lesser extent as expected, since many antibodies are known to
recognize the glycosylated forms of HIV Env.
Immunogenicity of Env CE DNA vaccine in macaques
To test immunogenicity of the Env CE DNA vaccine, a
combination of the 2 Env CE plasmids was used to
Figure 2. Env CE1 and Env CE2 expression vectors. (A) Env-CE1 and Env CE2 proteins span 220 amino acids distributed among 12 different CE. They are highly related, dif-
fering by 24 amino acids symbolized by asterisks, indicating number and location of the toggle AA. The Env CE1 and Env CE2 complete sequences are each 282 amino
acids in length, including linkers (3 amino acids in length each) and a 29-amino acid BaL Env signal peptide. The linker sequence includes AAV, AAE, GAK, AAD, AAK, GAV,
VAV, or AAF. The Env CE1 and Env CE2 sequences were inserted in the CMVkan expression vector between the CMV promoter and the bovine growth hormone polyade-
nylation signal. (B) HEK293T cells were transfected with HIV pDNAs expressing Env CE1 (lane 1), Env CE2 (lane 2), Env gp145dID (lane 3–5). Lane 6 contains a sample from
mock-transfected cells. Proteins from the cell-associated (top panel: 1/100 of the sample) and extra-cellular (bottom panel: 1/200 of the sample) were analyzed. Western
immunoblots were probed using the rabbit anti-gp120 sera. Equal loading of the blot with the cell-associated fraction was controlled by probing the membrane with an
anti-actin antibody (middle panel). (C) Cell lysates from HEK293 cells transfected with plasmids expressing the HIV CE1, HIV CE2 and BaL gp145dID were treated with
Endo H, PNGase F or left untreated. The samples were analyzed by Western immunoblot assay using a rabbit anti-HIV gp120 antibody. (D) Subcellular localization of HIV
Env CE proteins is shown in HeLa-derived HLtat cells transfected with Env CE-FLAG plasmids. The HIV Env CE-FLAG proteins were visualized with anti-FLAG primary anti-
body followed by Alexa-Fluor 488 conjugated secondary antibody, and the nuclei were stained with DAPI (separate and merged images are shown).
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immunize 4 macaques (Fig. 3A) at 0, 2 and 4 months. The
animals were monitored for the development of CE-speciﬁc
T cell responses 2 weeks after the 2nd and the 3rd vaccina-
tion (V2, V3), and the durability of the responses was mon-
itored for 3 months after the 3rd vaccination (Fig. 3B). This
analysis demonstrated the presence of robust IFN-gC CE-
speciﬁc cellular immune responses (0.1–0.8% of T cells),
mediated primarily by CD8C T cells, in all 4 animals. We
interrogated both IFN-g as well as TNF-a T cell responses.
Since the TNF-a positive cells were also positive for IFN-g,
we focused our analysis on IFN-g responses which covers
all the T cell responses. In agreement with our previously
reported data, maximal T cell responses were obtained with
2 to 3 DNA vaccinations using EP as delivery method. The
Env CE vaccine induced both CD8C and CD4C memory T
cell responses of the central and effector phenotype
(Fig. 3C). The Env CE DNA vaccine also induced CE-spe-
ciﬁc responses with a signiﬁcant fraction of CD8C T cells
with cytotoxic phenotype (Granzyme BC and CD107aC)
(Fig. 3D), while the CD4C T cell responses with a cyotoxic
phenotype were very low. We further found that CE-speciﬁc
responses measured both as total as well as the subset of
cytotoxic T cells showed robust durability with »2-fold
contraction over the 2 months following the prime (V3wk2
to V4). Thus, the Env-CE DNA vaccine induced cellular
immune responses with the desired features for an effective
T cell vaccine.
Env CE prime/complete env DNA booster vaccination
We previously reported that CE within HIV and SIV Gag were
poorly immunogenic when present within the complete Gag
protein, likely due to either suboptimal processing and presen-
tation or immunological interference with other epitopes and
thus, unable to induce de novo responses.18,20 We further found
that the Gag CE-speciﬁc responses could be augmented upon
booster vaccination with DNA expressing full-length Gag. This
opens the possibility that Env CE-speciﬁc responses could be
subject to the same mechanism. To address this experimentally,
Env-CE DNA primed macaques received 2 env DNA booster
vaccinations (Fig. 4A). To optimally cover the 12 CE sequences
in Env CE1 and CE2, a mixture of 3 Env DNA, including BaL,
6101 and 1086, was used. Table 4 shows the alignment of the
Env CE1 and CE2 sequences and the corresponding sequences
in the selected Env proteins. Three of the 12 CE (CE6, CE7,
CE9) show 100% identity with the Env sequences used in the
booster vaccination, while the other CE sequences match
except for 1 or 2 toggle AA. We generated gp145 versions of
these Env proteins which (i) span the sequence covered by the
CE and (ii) lack the immunodominant (ID) region in the extra-
cellular gp41. Expression of these Env proteins is shown in
Fig. 2B.
Implementation of the prime-boost regimen using the Env-
CE DNA prime followed by the intact Env DNA boost (vacci-
nation 4 and 5, Fig. 4A), demonstrated a signiﬁcant 4–10-fold
increase of CE-speciﬁc cellular responses in the 4 animals
(Fig. 4B). In fact, 2 env DNA booster vaccinations lead to very
robust levels of CE-speciﬁc immune responses (0.7–3% of total
T cells). Thus, although inefﬁcient in inducing primary
responses to the CE, boosting with the intact Env DNA
potently augmented pre-existing immunity demonstrating that
the peptides within the CEs are properly processed and pre-
sented. This vaccine regimen achieved an effective shift in the
immunological hierarchy, similar to our previously reported
ﬁnding with HIV and SIV Gag vaccinations in macaques.18,20
Figure 3. Env CE DNA vaccine induces T cell responses in macaques. (A) Cartoon
shows the vaccination regimen used to prime of macaques. The animals were vac-
cinated 3x with a mixture of Env CE1 and Env CE2 DNA by intramuscular injection
followed by in vivo electroporation. T cell responses were analyzed after the 2nd
and 3rd vaccination and 3 months later. (B) CE-speciﬁc T cell responses (both CD4
and CD8) measured 2 weeks after the second and third vaccination, as well as
3 months later, in PBMC samples stimulated with a peptide pool covering all 12
CE. The percent of CE-speciﬁc IFN-gC T cells upon peptide stimulation is shown.
(C) The % CE-speciﬁc IFN-gC producing CD4 and CD8 central memory (CM;
CD28CCD95C) and effector memory (EM; CD28¡CD95C) T cells was determined
following peptide stimulation with the CE peptide pool. (D) CE-speciﬁc responses
are cytotoxic. The percentage of IFN-gC producing CE-speciﬁc CD4 and CD8 T cells
harboring Granzyme B and expressing CD107a was determined following stimula-
tion by the CE peptide pool.
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Furthermore, the Env CE responses were monitored 8 months
after the 2nd booster vaccination (Fig. 4B); these measurements
showed 2- to 4-fold contraction compared with peak
responses, supporting robust longevity of the CE-speciﬁc T cell
memory responses.
In addition, boosting with intact env DNA led to a propor-
tional increase in CD4C and CD8C effector memory responses
(Fig. 4C). Boosting with intact env DNA further augmented the
levels of cytotoxic (Granzyme BC CD107aC) CD4C and CD8C
T cell responses (Fig. 5; note that different scales were used).
Flow analysis (Fig. 5A) showed the Granzyme B content
and ability to degranulate (CD107aC) by the CE-speciﬁc CD4C
and CD8C T cells. The levels of both cytotoxic CD4C (Fig. 5B)
and CD8C (Fig. 5C) T cells increased. We found that the robust
levels of the CD8C T cell subset showed remarkable durability
over the 8 months of follow-up, with a median 2-fold
contraction.
Mapping of the Env CE responses
To evaluate the immunogenicity of individual CE, PBMC were
stimulated with 12 CE-speciﬁc pools. IFN-gC T cell response is
plotted (Fig. 6) after the 3rd CE DNA prime and after the 2nd
Env DNA boost and the responses are summarized in Table 5.
Fine mapping showed that 6 of the 12 CE were immunogenic
after the 3rd CE DNA prime (Table 5; prime) including CE7,
Figure 4. Env CE prime-boost vaccination. (A) Cartoon shows the vaccine regimen used in the prime-boost vaccination of the macaques. The boost was performed with a
mixture of env DNA composed of clade B (BaL and 6101) and clade C (1086) env DNA covering the 23 CE sequences (including toggle AA) present in HIV Env CE1 and CE2
proteins. DNA was delivered by intramuscular injection followed by in vivo electroporation. (B) CE-speciﬁc T cell responses (both CD4 and CD8) measured at the time of
the booster vaccination (V4, V5) and 2 weeks later. The longevity of the memory responses was monitored 8 months later. (C) The proportion of the memory responses
was determined after the last booster vaccination. The % CE-speciﬁc IFN-gC producing CD4 and CD8 central memory (CM; CD28CCD95C) and effector memory
(EM; CD28¡CD95C) T cells was determined following stimulation with the peptide pool containing the 12 CE.
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CE8, CE9, CE11, CE14 and CE16, with 2–4 positive CE/animal.
A comparison of responses to individual CE before and after
boosting with DNA plasmids expressing intact Env showed
that 7 of the 12 segments (60%) of the HIV Env CE are immu-
nogenic. Responses to each individual CE were augmented fur-
ther upon boost vaccination. Some of the CE (CE6, CE1, CE10,
CE12 and CE15) did not show cellular responses in these ani-
mals. Interestingly, CE14, located in HR1 of gp41, appears to
be immunogenic both within intact Env (Table 3) and the Env
CE DNA vaccine (Table 5). We noted that upon booster vacci-
nation the appearance of additional positive CE in 3 of the ani-
mals (L985, P574 and R067). We speculate that ‘new’ responses
detectable only after the boost may reﬂect responses below
threshold of detection after the priming vaccination and maybe
the result of an overall increase in CE-speciﬁc response upon
intact env DNA booster vaccination. Of note, the mapping of
12 individual CE is likely affected by the overall magnitude of
the total CE response. For this reason, we believe that assess-
ment of median values of positive CE/animal best reﬂects the
data. In comparison to env DNA vaccinated animals (Table 2)
which showed a median of 1 positive CE/animal among maca-
ques mounting CE responses, the Env CE prime/env DNA
boost vaccine induces signiﬁcantly (p < 0.001) more positive
CE/animal (median 4 CE) (Table 5). These data demonstrate
that the CE prime/env DNA booster vaccination shifted the
hierarchy toward broader Env CE-speciﬁc T cell responses.
Figure 5. CE prime-env DNA boost elicits potent and durable cytotoxic T cell responses. (A) Dot plots shows the Granzyme B content and degranulation activity
(CD107aC) from unstimulated and peptide stimulated T lymphocytes from one vaccinated animals (P574) measured at 2 weeks after the 5th vaccination. The CD4C (left
panel) and CD8C (right panel) CE-speciﬁc IFN-gC T cells are shown in black. (B) Frequency of CE-speciﬁc cytotoxic CD4C T cell responses, and (C) CD8C T cell responses
after each booster vaccination are shown at 2 weeks after the priming (V3w2), after the 3 mo of rest at the day of the 1st booster vaccination (V4), 2 weeks later (V4w2),
after a 2 mo rest period at the day of the 1st booster vaccination (V5), 2 weeks later (V5w2) and 8 months later.
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Env CE DNA vaccine induced humoral immune responses
The Env CE DNA vaccine was also interrogated for its ability to
induce humoral immune responses. We tested whether anti-
bodies induced upon Env CE vaccination could recognize the
immunogen by Western immunoblot assay (Fig. 7A). The data
from 2 of the 4 animals (L985, P574) showed that the priming
vaccine induce antibodies that can detect the immobilized Env
CE protein on the membrane. The responses developed by the
other 2 macaques were below the threshold of detection. Upon
boosting with complete env DNA both animals (L985, P574)
showed stronger Env CE bands, indicating higher Env CE
antibody titers. We next tested whether these antibodies could
be detected by standard HIV gp120 Env ELISA. The antibodies
induced by Env CE priming vaccinations in one of the 4 ani-
mals (P574) could be detected by ELISA (Fig. 7B) and, as
expected, these antibodies further increased upon boost with
intact Env. We further tested whether the Env CE DNA vaccine
induced antibodies able to detect cross-clade Env (clade B and
clade C) by Western blot assay (Fig. 7C). Both animals (L985,
P574) showed that priming with Env CE induces antibodies
able to recognize not only the immunogen (Fig. 7A) but also
clade B and C Env, supporting the notion the antibodies recog-
nize shared conserved sequences, and these responses increased
Figure 6. Mapping of the CE responses after prime and boost. The % CE-speciﬁc IFN-gC T cells after prime (V3w2) and after boost (V5w2) are plotted. The 12 individual
peptide pools were used to determine the positive CE in the animals.
Table 4. Alignment of the Env CE and the HIV Env Sequences used in the booster vaccination.
CE# HIV Env Alignment of CE and HIV Env CE# HIV Env Alignment of CE and HIV Env
CE6 WVTVYYGVPVW CE11–1 DNWRSELYKYKVV
1086 WVTVYYGVPVW CE11–2 NNWRSELYKYKVV
6101 WVTVYYGVPVW 1086 DNWRSELYKYKVV
BaL WVTVYYGVPVW 6101 DNWRSELYKYKVV
BaL DNWRSELYKYKVV
CE1–1 HNVWATHACVPTDP CE12–1 ARRRVVQREKRA
CE1–2 HNIWATHACVPTDP CE12–2 AKRRVVEREKRA
1086 HNVWATHACVPTDP 1086 AKRRVVEREKRA
6101 HNVWATHACVPTDP 6101 AKRRVVEREKRA
BaL HNVWATHACVPTDP BaL AKRRVVQREKRA
CE7–1 ISLWDQSLKPCVKLTPLCVTL CE13–1 GFLGTAGSTMGAAS
CE7–2 ISLWDESLKPCVKLTPLCVTL CE13–2 GFLGAAGSTMGAAS
1086 ISLWDESLKPCVKLTPLCVTL 1086 GFLGAAGSTMGAAS
6101 ISLWDESLKPCVKLTPLCVTL 6101 GFLGAAGSTMGAAS
BaL ISLWDQSLKPCVKLTPLCVTL BaL GFLGAAGSTMGAAA
CE8–1 FEPIPIHYCTPAGFA CE14–1 LTVQARLLLSGIVQQQNNLLRAI
EAQQHLLQLTVWGIKQLQAR
CE8–2 FDPIPIHYCAPAGYA CE14–2 LTVQARQLLSGIVQQQSNLLKAIEA
QQHMLQLTVWGIKQLQTR
1086 FDPIPLHYCAPAGFA 1086 LTVQARQLLSGIVQQQSNLLRAIEA
QQHMLQLTVWGIKQLQAR
6101 FDPIPLHYCAPAGFA 6101 LTVQARQLLSGIVQQQNNLLRAIE
AQQHLLQLTVWGIKQLQAR
BaL FEPIPIHYCAPAGFA BaL LTVQARLLLSGIVQQQNNLLRAIEA
QQHLLQLTVWGIKQLQAR
CE9–1 VQCTHGIRPVVSTQLLLNGSLAE CE15–1 WLWYIKIFIMIVGGLVGLRI
CE9–2 VQCTHGIKPVVSTQLLLNGSLAE CE15–2 WLWYIRIFIMIVGGLIGLRI
1086 VQCTHGIKPVVSTQLLLNGSLAE 1086 WLWYIKIFIMIIGGLIGLRI
6101 VQCTHGIKPVVSTQLLLNGSLAE 6101 WLWYIKIFIMIIGGLIGLRI
BaL VQCTHGIRPVVSTQLLLNGSLAE BaL WLWYIKIFIMIVGGLIGLRI
CE10–1 SGGDPEIVMHSFNCGGEFFYC CE16–1 RVRKGYSPLSLQT
CE10–2 AGGDLEITTHSFNCRGEFFYC CE16–2 RVRQGYSPLSFQT
1086 SGGDLEITTHSFNCRGEFFYC 1086 RVRQGYSPLSFQT
6101 SGGDLEITTHSFNCRGEFFYC 6101 RVRQGYSPLSFQT
BaL SGGDPEIVTHSFNCGGEFFYC BaL RVRQGYSPLSFQT
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upon env DNA booster vaccinations. Env CE DNA priming
alone did not induce neutralizing antibodies (Nab), likely
reﬂected by the low ELISA titers. Upon 2 env DNA booster vac-
cinations, low Nab responses to tier 1A Env (MW965.26 in all 4
animals and SHIV SF162.P4 in 3 animals) were found. Overall
low titers of Nab are expected in the absence of a protein in the
vaccine.31,42,43 We also analyzed whether the Env CE priming
vaccination-induced antibodies could recognize linear peptides
by ELISA screening of a library of 20-mer peptides with 14 AA
overlap. As summarized in Table 6, all 4 animals showed
responses to various linear peptides, although to different
extents, and taken together peptides within CE6, CE9, CE10,
CE12, CE14 and CE16 were recognized. Together, the analysis
of the cellular and humoral immune responses induced by the
Env CE DNA vaccine showed the development of immune
responses able to recognize 10 of the 12 CE (located in C1, C2,
C3, C5 and gp41 regions).
Discussion
In this study, we expanded our HIV Conserved Element DNA
vaccine concept and developed a DNA vaccine that focuses the
immune responses to highly conserved sequences in Env. This
DNA induces robust immune responses to epitopes that are
only poorly immunogenic when present within intact Env.
Addition of a booster vaccination with DNA expressing com-
plete Env resulted in greatly increased Env immune responses
focusing on the otherwise suboptimal Env CE regions. Thus,
similarly to our reports with HIV and SIV Gag,18, 20, 21 priming
with a DNA vaccine expressing only CE alters the immune
hierarchy resulting in recognition of these subdominant epito-
pes. Interestingly, both for Env and Gag, the magnitude,
breadth and cytotoxic phenotype of the CE-speciﬁc responses
are signiﬁcantly increased upon boosting with DNA expressing
the full-length molecules. We hypothesize that the details of the
processing and presentation of epitopes from full-length Env
may be superior in their ability to augment pre-existing CE
immunity, however, they are unable to induce de novo CE-spe-
ciﬁc responses in »50% of the animals. The impairment of
inducing de novo responses is thought to be due to the presence
of dominant epitopes which suppress the development of the
subdominant CE-speciﬁc T cell responses. Thus, priming with
CE DNA and boosting with a plasmid expressing the intact
protein may be generally applicable and may solve a major
obstacle in HIV vaccine development, which is the focusing of
responses to rapidly mutating immunodominant epitopes. This
work demonstrates alteration of the hierarchy of epitope recog-
nition and development of immune responses to potentially
protective subdominant highly conserved epitopes.
The poor immunogenicity of the Env Conserved Elements
reported in this study was found in macaques immunized
with plasmid DNA encoding the complete Env protein. Sev-
eral trials reported Env epitope mapping using samples from
humans vaccinated with different forms of HIV-1 Env. Volun-
teers vaccinated with ADVAX37 or DNA/NYVAC38 developed
cellular immune responses targeting few epitopes with a total
coverage of around 20 different peptides (mean of 3 epitopes
per subject in the ADVAX study; 4.2 epitopes in the DNA/
NYVAC) with some of the reported peptides partially overlap-
ping or containing CE637-38 and CE1 and CE13.38 These data
suggest that the CE identiﬁed in our work are poorly immu-
nogenic also in persons vaccinated with the full-length Env.
Interestingly, many of the reported epitopes identiﬁed in
humans are MHC class II restricted and, therefore the major-
ity of the volunteers responding developed T cell responses
predominantly mediated by CD4C T cells. Similar results were
also obtained in the RV144 vaccine trial combining ALVAC
and bivalent HIV-1 gp120 as protein.39 In this study, which is
the only trial that has identiﬁed low level of protection against
infection, the vaccinated persons developed T cell responses
targeting an average of 2 epitopes in Env, with a vast majority
of these responses being mediated by CD4C T cells, in many
cases recognizing peptides in the V2 region containing the
a4b7 integrin binding site.40 Predominant CD4C T cells
responses in volunteers immunized with different forms of
HIV-1 Env were already identiﬁed in the early 1990s by Oren-
tas et al, using samples from humans immunized with recom-
binant HIV-1 gp160.41 In contrast, the vaccine regimen
described in this work (priming with Env CE DNA and boost-
ing with the complete molecule) induces a balanced immune
response mediated by both CD4C and CD8C T cells with cyto-
toxic phenotype and broad epitope recognition. It remains to
be determined whether the macaque data reported here show-
ing strong CD8C T cell responses could be recapitulated after
human immunization.
The data presented in this report provide a vaccine regimen
able to induce potent T cell responses to subdominant epito-
pes. The question then arises whether the induced humoral
immune responses are of better functional quality. A DNA
only vaccine regimen is hampered by its inability to induce
maximal antibody responses which can only achieve upon
protein boost or co-immunization with protein.42,43 Such
studies will be necessary to evaluate the full potential of the
CE DNA vaccine regimen and we have already found that the
CE DNA vaccine can induce responses to regions in Env that
are only poorly immunogenic in macaques vaccinated with
full-length env DNA. Thus, the Env CE DNA vaccine regimen
has the potential to further positively affect humoral immune
response development.
Table 5. Mapping of CE responses after Env CE DNA prime and after env DNA
boost.
L985 R288 P574 R067
Individual CE Prime Boost Prime Boost Prime Boost Prime Boost
CE1
CE6
CE7 C C C C C
CE8 C C C C C
CE9 C C
CE10
CE11 C C C
CE12
CE13 C
CE14 C C C C C C
CE15
CE16 C C C C C C
No. of positive
CE/animals
3 4 4 4 2 5 2 4
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2867
Materials and methods
Plasmids
Plasmids HIV Env CE1 (plasmid 329H) and Env CE2
(plasmid 331H) contain the RNA/codon-optimized Env CE
genes inserted into pCMVkan vector36 between the human
CMV promoter and BGH polyadenylation signal. Both pro-
teins contain the HIV BaL Env signal peptide at the N-termi-
nus. Insertion of a FLAG-tag at the C–terminus of Env CE1
and Env CE2 generated plasmids 327H and 330H,
respectively. HIV gp145dID (plasmid 332H, 341H and 340H)
are based on HIV-1 clade B strain BaL, 6101 and clade C
1086, respectively, and express HIV gp145 Env (corresponding
to AA 1–727 of HXB2) lacking the extracellular gp41 immu-
nodominant region (corresponding to AA 590–608 of HXB2).
All HIV Env proteins were produced from an RNA/codon
optimized genes cloned into pCMVkan. Endotoxin-free DNAs
(Qiagen, Valencia, CA) were prepared according to the manu-
facturer’s protocol.
HIV Env CE DNA expression upon transient transfection
HEK293T cells seeded in 60 mm plates at a density of 106 cells/
plate and were transfected by the Calcium Phosphate DNA co-
precipitation procedure using 0.5 mg HIV env CE or 0.1 mg
HIV gp145 env plasmid DNA together with 7 mg Bluescript as
carrier DNA. Six hours after transfection the medium was
replaced with 3 ml of complete DMEM. After 2 days, superna-
tants and cells were harvested, and the cells were lysed in 1 ml
of hypertonic N1 lysis buffer (20 mM HEPES pH7.9, 10% glyc-
erol, 1 mM MgCl2, 400 mM NaCl, 0.5 mM DTT, 0.5% Triton
X-100), sonicated brieﬂy for 2 £ 6 seconds and centrifuged at
14 000 rpm for 15 min at 4C. Endoglycosidase treatments
were performed using 20 microliter cell lysates from HEK283
transfected cells. The cells were transfected with 1 mg DNA CE
DNA and 0.2 mg env DNA, respectively. Extracts were
untreated or digested for 1 hr at 37 C with endoglycosidase H
(EndoH) or N-Glycosidase F (PNGase F) (New England Biol-
abs, Inc., Ipswich, MA), respectively, following the manufac-
turer’s instructions. Protein expression was analyzed by
Western immunoblots using 12% sodium dodecyl sulfate poly-
acrylamide gels (Nu-Page Bis-Tris, NuPAGE, Invitrogen, Life
Technologies Corp., Carlsbad, CA) and blotted onto nitrocellu-
lose membranes which were probed with a rabbit anti-HIV
gp120 antibody (dilution 1:2000), followed by anti-Rabbit IgG-
HRP labeled antibody (1:10,000 dilution, GE Healthcare, Pis-
cataway, NJ). As control, the membranes were probed with
anti-actin antibody (clone C4, EMD Millipore, Billerica, MA)
at a dilution of 1:10,000. The bands were visualized using the
enhanced chemiluminescence (ECL) Prime Western blotting
detection system (GE HealthCare, Piscataway, NJ).
Figure 7. Humoral immune responses upon prime/boost. (A) Western immunoblot
analysis was used to probe the Env CE proteins using plasma from vaccinated mac-
aques. Proteins from cells transfected with a combination of HIV Env CE1 and Env
CE2 plasmids were separated on denaturing gels and transferred onto membranes.
Individual strips of membranes were incubated with plasma (1:100 dilution) from
the vaccinated macaques and visualized using standard western blot methodol-
ogy. (B) The Env CE DNA vaccine prime induced antibodies that can recognize
gp120 Env by ELISA (HIV-1 IIIB) in animal P574. The responses were boosted by
each of the full-length env DNA vaccination (4th and 5th vaccination V4w2, V5w2).
(C) Antibodies induced by the HIV Env CE DNA vaccinated macaques recognize
intact HIV Env proteins from both clade B (BaL gp145dID) and clade C (1086
gp145dID). HIV Env gp145 protein from transfected cells was separated on dena-
turing gels and transferred onto membranes. The membranes were incubated
with plasma (dilution 1:100) from macaque L985 and P574 primed with Env CE
DNA (3rd vaccination, V3wk2) and boosted with intact env DNA (5th vaccination,
V5wk2). Proteins from mock-transfected cells served as a negative control.
Table 6. Summary of CE immunity in the 4 env CE DNA vaccinated macaques.
CE# Location
Cellular Responses
to Individual CE
Humoral Responses
to Linear Peptides
Immunogenic
CE
CE1 C1
CE6 C1 C C
CE7 C1 C C
CE8 C2 C C
CE9 C2 C C C
CE10 C3 C C
CE11 C5 C C
CE12 C5 C C
CE13 FP C C
CE14 gp41 C C C
CE15 gp41
CE16 gp41 C C C
# of positive CE
(N D 12)
7 6 10
FP, fusion peptide; C1 to C5, conserved Env regions
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Immunoﬂuorescence assay
The HeLa-derived HLtat cells (2 £ 105 cells/35 mm glass-bot-
tomed plate) were transfected with 200 ng of HIV Env CE1-
FLAG (plasmid 327H) and Env CE2-FLAG (330H). After 24 h,
the cells were ﬁxed with 4% paraformaldehyde in PBS, permea-
bilized with 0.5% Triton-X 100 in PBS, incubated with mouse
anti-FLAG antibody (#F1804, Sigma, St. Louis, MO), followed
by incubation with anti-mouse antibody conjugated with
Alexa-Fluor 488 (Life Technologies, Carlsbad, CA, at 1:750
dilution each) as secondary antibodies. The nuclei were stained
with DAPI (Life Technologies, Carlsbad, CA). Cells were visu-
alized on a Zeiss Observer Z1 ﬂuorescent microscope using
Zeiss Axiovision software (Carl Zeiss Microimaging GmbH,
G€ottingen, Germany).
Vaccination of Rhesus macaques
This study was performed in accordance with the Guide for the
Care and Use of Laboratory Animals of the National Institutes
of Health. Indian rhesus macaques were housed and handled in
accordance with the standards of the Association for the
Assessment and Accreditation of Laboratory Animal Care
International at the Advanced BioScience Laboratories Inc.,
MD, and were approved by the Institutional Animal Care and
Use Committee (OLAW assurance number A3467–01 and
USDA Certiﬁcate number 51-R-0059). All DNA vaccine mix-
tures contained 0.2 mg of expression-optimized macaque IL-12
DNA (plasmid AG157).
Four macaques (L985, P574, R067 and R288) received 3
DNA priming vaccinations using a mixture containing 1 mg
(vaccination 1 and 2) or 2 mg (vaccination 3) of each HIV Env
CE1 amd Env CE2 plasmids. The env pDNA booster vaccina-
tion used 1 mg of each of the 3 HIV gp145dID plasmids (BaL,
6101, 1086). The pDNA vaccine was formulated in water and
delivered via i.m. injection at 2 different sites (0.3 ml each site)
followed by in vivo electroporation (IM/EP) using the Elgen
1000 device (Inovio Pharmaceuticals Inc., Plymouth Meeting,
PA).
Two groups of macaques (total 16 animals) were vaccinated
with intact env DNA as part of other studies and PBMC col-
lected after the last vaccination were analyzed for Env CE and
total Env-speciﬁc responses for this study. Seven macaques
(T134 through T151) were vaccinated (V1, V2 and V3) with a
mixture of 2 mg of the 3 HIV gp145dID pDNA (mixture of
HIV-1 clade B BaL and 6101, and clade C 1086) formulated in
phosphate-buffered saline solution. The pDNA vaccine was
delivered via i.m. injection at one site (0.5 ml) followed by
in vivo electroporation with the CELLECTRA 5P device (Ino-
vio Pharmaceuticals, Inc., Plymouth Meeting, PA). Nine maca-
ques (P909 through P941 starting by the letter “P”) were
vaccinated with a mixture of 3 mg of HIV expressing BaL,
6101, 1086 and EnvC (GenBank accession number
AAD12112.1) as gp160 (plasmids 217H, 98H, 284H, 158H)
and as gp140 (plasmids 229H, 228H, 285H, 246H) and the full-
length single-chain (FLSC) protein, a CD4-BaL gp120 fusion
protein (plasmid 203H). The pDNA mixtures was formulated
in phosphate-buffered saline solution and delivered via i.m.
injection at 2 different sites (0.5 ml each site) followed by in
vivo electroporation (IM/EP) using the ICHOR device (ICHOR
Medical Systems, San Diego, CA).
Intracellular cytokine staining
Ficoll-hypaque isolated PBMC were cultured in 96-well plates
in the presence of various peptide pools from HIV, at a ﬁnal
concentration of 1 mg/ml for each peptide. Two peptide pools,
combining 15-mer peptides overlapping by 11 AA and 10-mer
peptides overlapping by 9 AA (Inﬁnity Biotech Research &
Resource, Inc.) were prepared to cover all the CE. Pool 1 con-
tains 126 peptides and covers CE1, 7, 8, 9, 10, 13 and 16 and
pool 2 contains 125 peptides and covers CE6, 11, 12, 14, and
15. The Env CE-speciﬁc results are presented as the sum of the
2 pools. Analysis of total Env-speciﬁc responses was performed
using pools of 15-mer peptides spanning gp120 (using BaL pep-
tides) and gp41 (PTE pool). Antigen-speciﬁc T cells were mea-
sured by intracellular cytokine staining followed by
polychromatic ﬂow cytometry18,22 using the following cocktail
of cell surface antibodies: CD3-APCCy7 (clone SP34–2),
CD4-V500 (clone L200), CD8-Alexa Fluor-405 (clone 3B5,
Invitrogen, Carlsbad, CA), CD28-PerCP Cy5.5 (clone CD28.2,
BioLegend, San Diego, CA) and CD95-FITC (clone DX2) (BD
PharMingen, San Diego, CA). Ten minutes after addition of
peptides, the CD107a-eFluor 660 (clone eBioH4A3, eBioscience
San Diego, CA) or CD107a-PE antibody (clone eBioH4A3,
eBioscience San Diego, CA) was added. After cell permeabiliza-
tion, intracellular staining was performed using IFN-g-PE Cy7
(clone B27, BD PharMingen), TNF-a-Alexa Fluor 700 (clone
Mab11, BD PharMingen) and Granzyme B-PE antibodies or
Granzyme B-APC antibodies (clone GB12, Invitrogen). As neg-
ative and positive controls, PBMC were cultured in medium
without peptide pools or stimulated with PMA and calcium
ionophore (Sigma, St. Louis, MO). Peptide-stimulated samples
were considered positive if the responses were 2-fold higher
than that of unstimulated medium only control and greater
than 0.01 after subtracting the medium control value. Samples
were acquired on a LSR II or Fortessa ﬂow cytometer (BD Bio-
sciences, San Jose, CA), and the data were analyzed using
FlowJo software (Tree Star, Inc., Ashland, OR).
Humoral immune response analysis of DNA vaccinated
macaques
Plasma samples were heat-inactivated for 30 minutes at 56C.
Binding antibodies to HIV env CE immunogen and intact Env
were detected by Western immunoblot using cell extracts from
HEK293 cells transfected with 1 mg of env CE DNA and 0.5 mg
of env DNA (BaL gp145dID; 1086 gp145dID, respectively), sep-
arated on 12% SDS-PAGE, and the membranes were probed
with pooled plasma (at a 1:100 dilution) and the bands were
visualized with anti-monkey IgA, M, G-HRP antibody
(1:10,000 dilution; cat# 43R-IG050hrp; Fitzgerald Industries
International Inc., MA).22 The binding titers to HIV IIIB gp120
were determined by standard ELISA using serial dilutions of
plasma samples (Advanced Bioscience Laboratory, Rockville,
MD), measuring optical absorbance at 450 nm. Pepscan analy-
sis was performed using 20-mer peptides overlapping by 14 AA
derived from HIV BaL.
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